文献速递精神分裂症与精神病性障碍物质与行为成瘾心境障碍

社会脆弱性与精神健康及物质使用障碍的患病率和治疗

Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

研究基于2020年10月至2022年10月美国全国住户样本中4674名完成临床访谈的成人,分析社区层面社会脆弱性(SVM、ADI)与DSM-5过去一年精神障碍和物质使用障碍诊断及治疗的关系。控制混杂后,SVM与精神分裂症谱系障碍、阿片使用障碍、兴奋剂使用障碍、双相I型障碍、创伤后应激障碍及任何精神障碍诊断相关,但与重性抑郁障碍、广泛性焦虑障碍及任何物质使用障碍无显著关联;在精神分裂症谱系障碍患者中,社会脆弱性与精神健康治疗减少相关。

要点

  • 社会脆弱性指标与精神分裂症谱系障碍、阿片使用障碍、兴奋剂使用障碍诊断呈显著正相关。
  • 社会脆弱性指标与重性抑郁障碍、广泛性焦虑障碍及任何物质使用障碍无显著关联。
  • 在精神分裂症谱系障碍患者中,社会脆弱性与精神健康治疗减少相关。

核心结论

  • 与既往基于非临床症状调查数据的研究不同,本研究发现社会脆弱性与广泛性焦虑障碍或重性抑郁障碍无关联。
  • 社会脆弱性与精神分裂症谱系障碍、兴奋剂使用障碍和阿片使用障碍的患病率相关,并伴有相应治疗减少。
  • 作者认为社会脆弱性指标可能有助于发展整合医疗与社会照护的更全面照护模式。

研究设计与样本

  • 研究为2020年10月至2022年10月间对美国全国住户样本进行的一项调查,采用多阶段、整群、分层区域概率抽样。
  • 分析纳入4674名完成临床访谈的成人(女性2904名[62.13%],男性1770名[37.87%];平均[标准差]年龄41.51[13.41]岁)。
  • 因难以区分精神障碍与痴呆症状,排除了65岁以上成人。
  • 住户样本排除了居住在监狱、州精神病医院和无家可归者收容所的成人。
  • 在住户样本中选择进行临床访谈的12906名成人中,4674名完成了临床访谈。

主要发现

  • 控制混杂因素后,SVM与精神分裂症谱系障碍诊断相关(aOR 17.22;95%CI 3.05-97.29)。
  • SVM与阿片使用障碍诊断相关(aOR 9.47;95%CI 2.30-39.02),与兴奋剂使用障碍诊断相关(aOR 6.60;95%CI 2.01-21.67)。
  • SVM与双相I型障碍诊断相关(aOR 2.39;95%CI 1.19-4.80),与创伤后应激障碍诊断相关(aOR 1.63;95%CI 1.06-2.50),与任何精神障碍诊断相关(aOR 1.44;95%CI 1.14-1.83)。
  • SVM与重性抑郁障碍、广泛性焦虑障碍或任何物质使用障碍无显著关联。
  • ADI结果与SVM相似但幅度普遍较低:精神分裂症谱系障碍aOR 11.38(95%CI 1.61-80.58),阿片使用障碍aOR 2.05(95%CI 0.30-14.10),兴奋剂使用障碍aOR 2.18(95%CI 0.52-9.18)。

关键数值与推荐

  • 在精神分裂症谱系障碍患者中,社会脆弱性与精神健康治疗减少相关(aOR 0.001;95%CI 0.00-0.18)。
  • 在阿片使用障碍或兴奋剂使用障碍患者中,社会脆弱性与物质使用障碍治疗减少相关(aOR 0.24;95%CI 0.02-2.80)。
  • 主要结局为DSM-5过去一年精神障碍和物质使用障碍的结构化临床访谈诊断,以及关于所接受治疗的调查问题回答。
  • 社会脆弱性采用社会脆弱性指标(SVM)和区域剥夺指数(ADI)在居住邮编区域层面确定。

临床怎么用

  • 作者认为SVM可能有助于发展更全面的照护模式,将医疗与社会照护整合用于精神障碍和物质使用障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Community-level social vulnerability (SV) is associated with physical illness and premature mortality. Its association with mental health (MH) and substance use disorders (SUDs) needs further study. OBJECTIVE: To study associations of SV with clinical diagnoses of MH disorders, SUDs, and related treatments in the US noninstitutionalized population of adults aged 18 years and older. DESIGN, SETTING, AND PARTICIPANTS: A survey of adults in a national sample of US households between October 2020 and October 2022. Participants drawn from a multistage, clustered, and stratified area probability sample of US households were included, excluding adults older than 65 years because of the difficulty of differentiating mental disorders from symptoms of dementia. The sample also included adults living in prisons, state psychiatric hospitals, and homeless shelters who were excluded from the sample of US households used in these analyses. Each sample household was sent a letter explaining the study and offering the option to complete the household roster online, by phone, or by email. Of the 12 906 adults selected for clinical interviewing in the household sample, 4674 completed clinical interviews. MAIN OUTCOMES AND MEASURES: Main outcomes were Structured Clinical Interview for DSM-5 past-year diagnoses of MH disorders and SUDs and responses to survey questions regarding treatment received. The Social Vulnerability Metric (SVM) and the Area Deprivation Index (ADI) were used to determine SV at the residential zip code level. RESULTS: The analysis involved 4674 participants (2904 [62.13%] female and 1770 [37.87%] male; mean [SD] age, 41.51 [13.41] years). Controlling for measured confounders, the SVM was significantly associated with diagnoses of schizophrenia spectrum disorder (SSD; adjusted odds ratio [aOR], 17.22; 95% CI, 3.05-97.29), opioid use disorder (OUD; aOR, 9.47; 95% CI, 2.30-39.02), stimulant use disorder (aOR, 6.60; 95% CI, 2.01-21.67), bipolar I disorder (aOR, 2.39; 95% CI, 1.19-4.80), posttraumatic stress disorder (aOR, 1.63; 95% CI, 1.06-2.50), and any MH disorder (aOR, 1.44; 95% CI, 1.14-1.83), but not major depressive disorder (MDD), generalized anxiety disorder (GAD), or any SUD. Results were similar for the ADI but generally of lower magnitude (SSD aOR, 11.38; 95% CI, 1.61-80.58; OUD aOR, 2.05; 95% CI, 0.30-14.10; stimulant use disorder aOR, 2.18; 95% CI, 0.52-9.18). Among participants with SSDs, SV was associated with reduced MH treatment (aOR, 0.001; 95% CI, 0.00-0.18) and reduced SUD treatment in participants with OUD or stimulant use disorder (aOR, 0.24; 95% CI, 0.02-2.80). CONCLUSIONS AND RELEVANCE: In contrast to previous studies using nonclinical symptom-based survey data, we found no association between SV and GAD or MDD. By contrast, there were associations of SV with prevalence of SSD, stimulant use disorder, and OUD with corresponding decreases in treatment. These results suggest that the SVM might assist in developing more comprehensive care models that integrate medical and social care for MH disorders and SUDs.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gibbons RD, Olfson M, Saulsberry L, et al. Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders. JAMA Psychiatry. 2024. PMID: 39046728. doi:10.1001/jamapsychiatry.2024.1870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。